New mouse model is created to help reduce the costs associated with drug testing and approval
Cancer is still one of the most prevalent diseases in the U.S., affecting millions of people each year.
Cancer is still one of the most prevalent diseases in the U.S., affecting millions of people each year. Thanks to advancements in research and technology, there are medications available that may help reduce tumor progression. Some breast cancer patients are advised to buy Tamoxifen to slow the spread of the illness.
Recently, a study from Goethe University revealed that a new mouse model has been developed to help improve the cost effectiveness of the testing and approval process for cancer drugs.
The researchers published their findings in the current issue of the journal Nature Communications.
"Our work is a feasibility study which considers whether [certain] mouse models are suitable for predicting the toxicity of targeted cancer drugs," said lead author Klaus Strebhardt. "This new animal model provides information on mechanism-based toxicities which could occur as a result of the pharmacological inhibition of [cancer genes like] Plk1."
He added that this type of research can be applied to many other target genes involved in a variety of different cancers.
|
